U.S. Markets close in 5 hrs 8 mins

Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more

Ron Leuty
Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more

How Genentech — with the help of a $1.7 billion merger — is breaking new ground in cancer … and more in our Health Care Digest.